Jane Street Group LLC Acquires New Shares in Autolus Therapeutics plc (NASDAQ:AUTL)

Jane Street Group LLC purchased a new position in shares of Autolus Therapeutics plc (NASDAQ:AUTL) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 11,271 shares of the company’s stock, valued at approximately $26,000.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Candriam S.C.A. purchased a new position in Autolus Therapeutics in the fourth quarter valued at $7,500,000. Wellington Management Group LLP lifted its holdings in shares of Autolus Therapeutics by 4.6% in the 4th quarter. Wellington Management Group LLP now owns 25,345,680 shares of the company’s stock valued at $59,562,000 after purchasing an additional 1,125,454 shares during the last quarter. BIT Capital GmbH increased its position in Autolus Therapeutics by 147.0% in the 4th quarter. BIT Capital GmbH now owns 636,979 shares of the company’s stock valued at $1,497,000 after acquiring an additional 379,050 shares during the period. Renaissance Technologies LLC increased its position in Autolus Therapeutics by 146.7% in the 4th quarter. Renaissance Technologies LLC now owns 618,942 shares of the company’s stock valued at $1,455,000 after acquiring an additional 368,071 shares during the period. Finally, Legal & General Group Plc increased its position in Autolus Therapeutics by 392.0% in the 4th quarter. Legal & General Group Plc now owns 297,736 shares of the company’s stock valued at $697,000 after acquiring an additional 237,224 shares during the period. 72.83% of the stock is currently owned by hedge funds and other institutional investors.

Autolus Therapeutics Price Performance

Shares of Autolus Therapeutics stock opened at $2.35 on Tuesday. The company has a market capitalization of $625.43 million, a PE ratio of -1.94 and a beta of 1.76. Autolus Therapeutics plc has a 1-year low of $1.11 and a 1-year high of $5.00. The business has a 50-day moving average of $1.48 and a 200-day moving average of $1.96.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.02). The company had revenue of $8.98 million during the quarter, compared to analyst estimates of $1.59 million. On average, equities analysts expect that Autolus Therapeutics plc will post -0.94 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have issued reports on AUTL shares. Truist Financial dropped their target price on Autolus Therapeutics from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, April 1st. Wells Fargo & Company cut their target price on Autolus Therapeutics from $8.00 to $6.00 and set an “overweight” rating on the stock in a research report on Friday, March 21st. Finally, Needham & Company LLC reissued a “buy” rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a research report on Thursday, April 10th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $9.32.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.